SEOUL-VIOSYS
18.6.2020 10:30:04 CEST | Business Wire | Press release
Seoul Viosys (KOSDAQ: 092190), a leading compound semiconductor solution provider, announced that its ultraviolet LED Violeds technology – the world’s first UV LED technology proven to sterilize new coronaviruses – has been adopted for the new “Fresh Air” brand of air conditioners produced by Gree Electric Appliances Inc. (Gree), the largest Chinese manufacturer of air conditioners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005326/en/
The Violeds UV LED technology adopted for the Gree “Fresh Air” air conditioner is a differentiated UV technology that provides robust disinfection on the surface of evaporator, as well as sterilization of any indoor airborne contaminants drawn into the air conditioner, including various harmful viruses and bacteria, ensuring that fresh air is continuously discharged. Conventional household air conditioners typically draw outside air into the AC unit, and discharge that air back into the interior after cooling and filtering, where it is continuously recirculated. This recirculation of indoor air may cause a higher risk of infection through aerosol transmission when viruses are present.
Through the results of testing by Guangzhou Institute of Microbiology in China (CGMT), Gree demonstrates that its new “Fresh Air” air conditioner with Violeds UV LED technology has the performance to sterilize 99.15% of viruses and bacteria, 98% of enteroviruses such as EV71 and H1N1, and 99% of staphylococcus albus bacteria. In addition, according to the results of testing conducted in April and May 2020 by the research group of Korea University, Violeds UV LED technology has been proven to sterilize 99.9% of the new coronavirus in 30 seconds. Seoul Viosys provides major customers with optimized UV LED solutions based on these successful testing results.
“Since air conditioning systems operate by circulating indoor air drawn in and discharged again, aerosol transmission is a concern when using these systems. In South Korea, health authorities rolled out a new guideline for citizens to prevent aerosol transmission, which included advising people to open windows every two hours when using their air conditioners,” said Chae Hon Kim, executive vice president of Seoul Viosys. “We offer an optimized solution to simultaneously enable disinfection of viruses in air, as well as air purification by disinfecting the air drawn into air conditioner and eliminating viruses in air using Violeds technology. As more applications adopt the Violeds technology to support healthy life, the cost of UV LEDs is anticipated to be reduced to a level closer to visible white LEDs.”
“Seoul Viosys’ Violeds technology has been adopted not only by the Chinese AC manufacturer Gree, but also by RGF Environmental Group, the leading in-duct air treatment supplier in the U.S. As a result of receiving production approval to supply Violeds products to these two leading global companies, Violeds UV LEDs have clearly been recognized as essential technology for air purifiers and air conditioning systems,” added Kim.
Violeds optical semiconductor technology is a new concept of clean technology developed by Seoul Viosys, starting with a 2005 collaboration with SETi in the U.S. Seoul Viosys’ UV LEDs are used in more than 4,000 patented technology brands worldwide to prevent viruses and bacteria from proliferating through exposure to ultraviolet light. With more than 1,000 patents secured and verified for the application of Violeds technology, the company has succeeded in extending its lifespan of its UV LED devices to 50,000 hours, and they have been widely adopted for air conditioners, air purifiers, water purifiers and multi-disinfection devices.
About Seoul Viosys
Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Micro Clean Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2018). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Micro Clean Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005326/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 14:01:00 CEST | Press release
DCX introduces groundbreaking new safety standard protecting critical AI infrastructure by monitoring and keeping the entire coolant loop Continuous monitoring of eight coolant parameters and automatic dosing keep hall-scale liquid-cooling loops in specification between service visits Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 14:00:00 CEST | Press release
Company’s Third Largest Shareholder Expects Update on Increased Transparency, Strategic Review of Xerox Financial Services Business Unit, and Continued DeleveragingSTARTEEPO Chairman František Bostl to Address Xerox Investment at Skytop Conference in London STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executin
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release
Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release
New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release
More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
